Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. due to allegations of violations of federal securities laws related to misleading statements about the efficacy and safety of its RGX-111 trial study [3]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against REGENXBIO [2]. - The complaint alleges that REGENXBIO and its executives made false and/or misleading statements and failed to disclose material adverse facts concerning the RGX-111 trial [3]. Group 2: Clinical Hold and Stock Impact - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy following a case of neoplasm in a trial participant [4]. - The FDA also placed a clinical hold on RGX-121 for similar reasons, leading to a stock price drop of $2.40 per share, or 17.9%, closing at $11.01 per share on the same day [4]. Group 3: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in REGENXBIO to contact them directly to discuss their legal options [1]. - The firm is also seeking information regarding REGENXBIO's conduct from whistleblowers, former employees, and shareholders [6].

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of monday.com Ltd. (NASDAQ: MNDY) between September 17, 2025 and February 6, 2026, both dates inclusive (the “Class Period”), of the important May 11, 2026 lead plaintiff deadline. SO WHAT: If you purchased monday.com common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange ...

Core Viewpoint - Driven Brands Holdings Inc. is facing a federal securities class action due to allegations of false and misleading statements regarding its financial condition and internal controls over financial reporting [4][5]. Group 1: Legal Action and Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Driven Brands and reminds investors of the May 8, 2026 deadline to seek the role of lead plaintiff in the class action [2]. - The complaint alleges that Driven Brands and its executives violated federal securities laws by failing to disclose inaccuracies in financial reports filed with the SEC from May 9, 2023, to November 5, 2025 [4]. - The firm encourages anyone with information regarding Driven Brands' conduct to contact them, including whistleblowers and former employees [8]. Group 2: Financial Misstatements and Impact - Driven Brands announced a delay in releasing its fiscal year 2025 financial results and will restate its financial statements for 2023 and all quarterly and full-year financial statements for 2024 due to material accounting errors [5]. - The company identified material weaknesses in its internal controls over financial reporting, which contributed to the inaccuracies [5]. - Following the announcement of these issues, Driven Brands' stock price dropped over 30% on February 25, 2026 [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Camping World Holdings, Inc. due to allegations of violations of federal securities laws, encouraging affected investors to contact them for legal options [2][4]. Financial Performance - Camping World reported a third quarter 2025 revenue of $766.8 million, a decrease of $58.1 million or 7.0% compared to the previous year, with a gross margin of 12.7%, down 81 basis points [5]. - In the fourth quarter of 2025, Camping World reported a net loss of $(109.1) million, an increase of $49.6 million or 83.3% from the previous year, with adjusted EBITDA at $(26.2) million, a loss increase of $23.7 million [6]. - The company’s total gross margin for the fourth quarter was 28.8%, a decrease of 247 basis points, and new vehicle gross margin was 12.3%, down 291 basis points [6]. Inventory Management and Operational Challenges - The complaint alleges that Camping World overstated its inventory management capabilities and retail demand, leading to a need for strict corrective inventory management objectives that negatively impacted gross profit and margins [4]. - The company implemented strict inventory management objectives to improve turnover rates, which created gross margin headwinds into 2026 [6]. Stock Performance - Following the release of third quarter results, Camping World's stock fell by $4.17, or 24.8%, closing at $12.65 per share on October 29, 2025 [5]. - After the fourth quarter results announcement, the stock price dropped by $1.79, or 16.5%, closing at $9.06 per share on February 25, 2026 [7]. Legal Proceedings - Investors who purchased securities in Camping World between April 29, 2025, and February 24, 2026, are reminded of the May 11, 2026, deadline to seek the role of lead plaintiff in a federal securities class action against the company [2][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the April 13, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought shares during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 13, 2026, to serve as lead plaintiff [2] - The lawsuit claims that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study and Biologics License Application (BLA) timeline [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]

Core Viewpoint - Driven Brands Holdings Inc. is facing a federal securities class action lawsuit due to allegations of misleading investors regarding its financial condition and internal controls over financial reporting during the class period from May 9, 2023, to February 24, 2026 [3][4]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that Driven Brands misled investors through inaccurate financial reports filed with the U.S. Securities and Exchange Commission, which included an unreconciled cash balance from 2023, leading to overstated revenue and cash, and understated operating expenses for 2023 and 2024 [3]. - On February 25, 2026, Driven Brands announced a restatement of certain financial results due to material errors, resulting in a share price decline of $5.01, or approximately 30.2%, from $16.61 on February 24, 2026, to $11.60 on February 25, 2026 [4]. Investor Actions - Investors who suffered significant losses are reminded of the May 8, 2026 deadline to seek the role of lead plaintiff in the class action, which allows them to oversee litigation and influence key decisions [1]. - Interested investors are encouraged to contact Kirby McInerney LLP for more information regarding their rights or interests related to the lawsuit [2][5]. Firm Background - Kirby McInerney LLP is a New York-based law firm specializing in securities litigation, with a history of achieving recoveries totaling billions of dollars for shareholders [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited due to allegations of securities law violations, encouraging affected investors to come forward before the April 13, 2026 deadline for lead plaintiff applications [2][5]. Group 1: Allegations Against Pomdoctor - The complaint alleges that Pomdoctor and its executives made false and misleading statements, failing to disclose involvement in a fraudulent stock promotion scheme and the use of offshore accounts for share dumping [5]. - Specific allegations include the omission of information regarding false rumors and artificial trading activity that inflated the stock price, leading to materially misleading public statements about the company's business and prospects [5]. Group 2: Stock Performance - Pomdoctor's share price experienced a significant decline of approximately 24%, dropping from about $0.50 per share on December 10, 2025, to around $0.38 per share on December 11, 2025, amid increased volatility and investor concerns about its financial performance [6]. Group 3: Legal Proceedings - The role of the lead plaintiff in the class action is to represent the interests of the class members, with any member able to apply for this role or remain an absent class member without affecting their ability to recover [7]. - Faruqi & Faruqi encourages individuals with information regarding Pomdoctor's conduct to contact the firm, including whistleblowers and former employees [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BlackRock TCP Capital Corp due to allegations of misleading statements and failure to disclose critical financial information, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 6, 2026 [4][6]. Financial Performance - BlackRock TCP's portfolio significantly weakened during the 2024 fiscal year, with the number of portfolio companies on non-accrual status more than doubling, leading to a 289% increase in debt investments on non-accrual status at cost, rising from 3.7% to 14.4% of the portfolio [7]. - The company's net asset value (NAV) fell by 22.44% year over year to $9.23 per share, with total losses (realized and unrealized) ballooning to $194.9 million for the fiscal year, a 186% increase year over year, largely due to a newly added $72.3 million net unrealized loss in the fourth quarter [7]. - On January 23, 2026, BlackRock TCP disclosed that its NAV per share as of December 31, 2025, was in the range of $7.05 to $7.09, representing a 19% decrease from the previous quarter and a 23.4% decrease from the prior year [8]. Stock Market Reaction - Following the February 27, 2025 press release regarding the weakened portfolio, BlackRock TCP's stock price fell by $0.90, or 9.64%, closing at $8.44 per share on unusually heavy trading volume [7]. - After the January 23, 2026 announcement of the revised NAV, the stock price dropped by $0.76, or 12.97%, closing at $5.10 per share on January 26, 2026, also on unusually heavy trading volume [9]. Legal Proceedings - The firm encourages investors who suffered losses in BlackRock TCP to contact them directly to discuss their legal options, emphasizing the importance of the April 6, 2026 deadline for seeking lead plaintiff status in the class action lawsuit [4][10].

Core Viewpoint - Nektar Therapeutics is facing a securities class action lawsuit due to allegations of issuing materially false and misleading statements regarding the REZOLVE-AA trial, which may have impacted the trial's integrity and results [2]. Group 1: Lawsuit Details - The class period for the lawsuit is from February 26, 2025, to December 15, 2025 [2]. - Allegations include failure to follow applicable instructions and protocol standards during the REZOLVE-AA trial, which is expected to have a significant negative impact on the trial's results [2]. - The lawsuit claims that the defendants' public statements were materially false and misleading throughout the relevant time [2]. Group 2: Shareholder Actions - Shareholders who purchased shares of NKTR during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for May 5, 2026 [3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - The article discusses a pending securities class action against Navan, Inc. (NASDAQ: NAVN) related to its October 2025 IPO, highlighting the deadline for investors to move for Lead Plaintiff status as April 24, 2026 [1][4]. Group 1: Lawsuit Details - The lawsuit, McCown v. Navan, Inc., filed in the U.S. District Court for the Northern District of California, aims to recover losses for investors who purchased Navan common stock during or traceable to the IPO [2]. - The complaint alleges that the IPO Registration Statement and Prospectus were false and misleading, omitting material facts regarding the company's financial trajectory [3]. Group 2: Financial Implications - Navan's sales and marketing expenses surged to approximately $95 million for the quarter ending October 31, 2025, representing a 39% increase from the previous quarter's $68.5 million [7]. - This increase in spending was deemed necessary to sustain the revenue and Gross Booking Volume (GBV) growth that was highlighted in the IPO documents [7]. - Following the announcement of the expense spike and the abrupt departure of CFO Amy Butte on December 15, 2025, Navan's stock experienced a nearly 12% drop in a single day, with shares declining from the IPO price of $25.00 to as low as $9.16, marking a 63% decrease for IPO investors [7].